Dataset Information
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
Ontology highlight
ABSTRACT: Background
Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy.Methods
Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM.Results
Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p?ConclusionsBoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy.
SUBMITTER: Landi L
PROVIDER: S-EPMC6868703 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
Publications
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
Journal for immunotherapy of cancer 20191121 1
<h4>Background</h4>Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy.<h4>Methods</h4>Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM.<h4>Results</h4>Cohort A accounted for 15 ...[more]